@article{MTMT:37341698, title = {S-GRAS score and the complementary prognostic value of neutrophil-to-lymphocyte ratio in adrenocortical carcinoma: evidence for a synergistic interaction}, url = {https://m2.mtmt.hu/api/publication/37341698}, author = {Bényei, Erik and Huszty, Gergely and Laki, András Miklós and Jakab, Zsuzsanna and Kiss, Gergely and Kovács, Attila and Borka, Katalin and Uhlyarik, Andrea and Eitler, Katalin and Igaz, Péter and Tőke, Judit and Tóth, Miklós}, doi = {10.3389/fendo.2026.1733138}, journal-iso = {FRONT ENDOCRINOL}, journal = {FRONTIERS IN ENDOCRINOLOGY}, volume = {17}, unique-id = {37341698}, issn = {1664-2392}, year = {2026}, eissn = {1664-2392}, orcid-numbers = {Borka, Katalin/0000-0002-8956-0770; Igaz, Péter/0000-0003-2192-554X; Tóth, Miklós/0000-0002-8701-408X} } @article{MTMT:37409718, title = {Safety and efficacy of once-daily oral paltusotine in acromegaly: ACROBAT Advance open-label extension up to 4 years}, url = {https://m2.mtmt.hu/api/publication/37409718}, author = {Gadelha, Monica R. and Gordon, Murray B. and Doknic, Mirjana and Mezosi, Emese and Tóth, Miklós and Randeva, Harpal and Boguszewski, Cesar Luiz and Davidson, Christopher and Casagrande, Alessandra and Jochelson, Theresa and Krasner, Alan}, doi = {10.1210/clinem/dgag254}, journal-iso = {J CLIN ENDOCR METAB}, journal = {JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM}, unique-id = {37409718}, issn = {0021-972X}, abstract = {Context Paltusotine is the first nonpeptide selective somatostatin 2 receptor agonist approved as once-daily oral treatment for acromegaly. Objective To evaluate long-term treatment with paltusotine in patients with acromegaly previously on an injected somatostatin receptor ligand (SRL)-based regimen. Methods ACROBAT Advance is an ongoing open-label extension (OLE) study. Interim results (up to year 4) are reported. Enrolled patients had completed a phase 2 parent study: ACROBAT Edge (baseline insulin-like growth factor I [IGF-I] >1 & times; upper limit of normal [ULN] on injected octreotide or lanreotide +/- cabergoline, or baseline IGF-I <= 1 & times;ULN with combination therapy or pasireotide) or ACROBAT Evolve (baseline IGF-I <= 1 & times;ULN on injected SRL monotherapy). Maximum paltusotine dose was initially 40 mg, then 60 mg, when a tablet formulation became available in year 3. Adjunctive treatment with cabergoline or pegvisomant was allowed as clinically indicated. Results Forty-three patients (88% of eligible patients from ACROBAT Edge and Evolve) enrolled in the OLE. Median (interquartile range) IGF-I levels were: 1.15 & times;ULN (0.84, 1.46) at parent study baseline (n = 43), 1.17 & times;ULN (0.98, 1.54) at Advance week 3 (n = 43), and 1.01 & times;ULN (0.83, 1.13) at Advance week 207 (n = 20). Growth hormone levels, acromegaly symptoms, and pituitary tumor size remained stable. Paltusotine was well tolerated, with no unexpected safety findings observed. As of this analysis, 8 (18.6%) patients had discontinued from the study, including 2 (4.7%) due to adverse events. Conclusion Once-daily oral paltusotine treatment was well tolerated and resulted in long-term disease control, including biochemical, symptom, and pituitary tumor stability, for up to 4 years.}, keywords = {IGF-I; MULTICENTER; GROWTH-FACTOR-I; Long term; paltusotine; somatostatin receptor ligand; somatostatin 2 receptor}, year = {2026}, eissn = {1945-7197}, orcid-numbers = {Tóth, Miklós/0000-0002-8701-408X} } @article{MTMT:36410343, title = {Dermatologic Features of Endocrine Tumor Syndromes-Systematic Review and Meta-Analysis}, url = {https://m2.mtmt.hu/api/publication/36410343}, author = {Pálla, Sára Judit and Metyovinyi, Zseraldin and Meznerics, Fanni Adél and Mirzahosseini, Arash and Tőke, Judit and Tóth, Miklós and Butz, Henriett and Patócs, Attila Balázs and Medvecz, Márta}, doi = {10.1111/ijd.70118}, journal-iso = {INT J DERMATOL}, journal = {INTERNATIONAL JOURNAL OF DERMATOLOGY}, volume = {65}, unique-id = {36410343}, issn = {0011-9059}, abstract = {Endocrine tumor syndromes, including multiple endocrine neoplasia types 1, 2A, and 2B (MEN1, MEN2A, MEN2B), Carney complex (CNC), and PTEN hamartoma tumor syndrome (PHTS), are hereditary conditions characterized by multisystem tumor development. Alongside endocrine neoplasms, these syndromes present with diverse cutaneous manifestations, offering valuable diagnostic clues for early recognition and management. This systematic review and meta-analysis aimed to evaluate and synthesize the dermatologic features associated with these syndromes. Following PRISMA 2020 guidelines, a systematic search of MEDLINE, Cochrane Library, and Embase databases was conducted. Eligible publications included original articles, case reports, and case series with detailed dermatological descriptions of patients with the aforementioned syndromes. Data extraction and risk of bias assessment were performed independently by multiple reviewers. Statistical analyses and data visualization were conducted using program package R. A total of 217 studies comprising 833 patients were included: 276 MEN1, 48 MEN2A, 9 MEN2B, 121 CNC, and 452 PHTS cases. Distinct dermatologic patterns emerged within each syndrome: angiofibromas, collagenomas, and lipomas in MEN1; cutaneous lichen amyloidosis in MEN2A; mucosal neuromas in MEN2B; lentiginosis and cutaneous myxomas in CNC; and trichilemmomas, papillomatous papules, and acral keratoses in PHTS. Melanoma prevalence was 2.2% in PHTS and 2.5% in MEN1 patients, underscoring the need for dermatologic vigilance. This review highlights the role of dermatologic assessment in identifying endocrine tumor syndromes, with cutaneous findings often serving as early, accessible markers of systemic disease. Enhanced awareness of these manifestations can facilitate timely genetic evaluation, cancer surveillance, and multidisciplinary intervention. Trial Registration: PROSPERO registration number: CRD42024558093.}, keywords = {amyloidosis; lipoma; multiple endocrine neoplasia; Carney complex; Genetic skin diseases; multiple hamartoma syndrome; primary cutaneous}, year = {2026}, eissn = {1365-4632}, pages = {464-488}, orcid-numbers = {Pálla, Sára Judit/0000-0002-9614-4724; Metyovinyi, Zseraldin/0009-0006-2553-1571; Mirzahosseini, Arash/0000-0002-3281-8435; Tóth, Miklós/0000-0002-8701-408X; Butz, Henriett/0000-0003-1664-409X; Patócs, Attila Balázs/0000-0001-7506-674X; Medvecz, Márta/0000-0002-3126-096X} } @article{MTMT:37380775, title = {Prevalence of somatic SF3B1R625H mutation in lactotroph tumours from a multi-centric cohort: a digital PCR-based study}, url = {https://m2.mtmt.hu/api/publication/37380775}, author = {Rai, Ashutosh and Barry, Sayka and Mangili, Federica and Barbieri, Anna Maria and Scheich, Balint and Iacovazzo, Donato and Chatterjee, Debojyoti and Rice, Tom and Begalli, Federica and Roncaroli, Federico and Magid, Kesson and Suleyman, Oniz and Szücs, Nikolette and Tőke, Judit and Herrera-Martinez, Aura D. and Soto-Moreno, Alfonso and Lopez-Fernandez, Judith and G-Garcia, Miguel E. and Luque, Raul M. and Guaraldi, Federica and Mazzatenta, Diego and Gentilini, Francesca and Asioli, Sofia and Mangone, Alessandra and Locatelli, Marco and Lania, Andrea G. and Tóth, Miklós and Dutta, Pinaki and Mantovani, Giovanna and Peverelli, Erika and Korbonits, Marta}, doi = {10.1093/ejendo/lvag098}, journal-iso = {EUR J ENDOCRINOL}, journal = {EUROPEAN JOURNAL OF ENDOCRINOLOGY}, volume = {194}, unique-id = {37380775}, issn = {0804-4643}, abstract = {Objective An SF3B1 (Somatic splicing factor 3B subunit 1) mutation has been associated with prolactin-secreting pituitary neuroendocrine tumours (PitNET) with increased proliferation, invasion, dopamine agonist resistance and reduced progression-free survival.Design We screened a multi-centric cohort of 127 patients with prolactin-secreting PitNET for the SF3B1R625H mutation using digital PCR.Methods A comparative analysis was conducted between wild-type and mutated tumours, assessing clinical parameters, including age at diagnosis, sex distribution, prolactin levels, tumour size, extent of invasion, recurrence, and response to dopamine agonists.Results Somatic SF3B1R625H mutation was found in 21/127 patients (17%), who were diagnosed at a younger age (P = .04) and had larger tumour diameter (P = .03). Patients who needed transcranial surgery had a higher mutation frequency in their tumour samples compared to the transsphenoidal group (P = .01). The occurrence of mutation was similar in males and females. Preoperative and postoperative prolactin levels were comparable in patients with mutant and wild-type tumours. No associations were observed between mutation and tumour invasiveness, Ki-67 proliferation index, p53 expression, recurrence and dopamine agonist resistance. Hypopituitarism at presentation, visual deficits, number of surgeries and disease-free survival were not different between the groups.Conclusion SF3B1 somatic mutation status in lactotroph tumours-as assessed by digital PCR technology-is associated with a younger age at diagnosis and larger tumour diameter. However, in our cohort, it does not appear to be associated with histological features, higher recurrence, treatment resistance, tumour invasiveness, or long-term outcomes in our multi-centric cohort.}, keywords = {MUTATION; CANCER; VARIANTS; IMPACT; Pituitary tumour; PITUITARY-ADENOMAS; SF3B1; droplet digital polymerase chain reaction; PitNet; Pituitary neuroendocrine tumours; Somatic variant; Multi-centric; lactotroph tumours}, year = {2026}, eissn = {1479-683X}, pages = {866-879}, orcid-numbers = {Szücs, Nikolette/0000-0002-6614-1311; Tóth, Miklós/0000-0002-8701-408X} } @article{MTMT:37011974, title = {Prevalence, risk factors and management of bone complications in Cushing's syndrome across Europe. Data from the European Registry on Cushing's syndrome (ERCUSYN)}, url = {https://m2.mtmt.hu/api/publication/37011974}, author = {Zdrojowy-Welna, Aleksandra and Amaral, Claudia and Araujo-Castro, Marta and Biermasz, Nienke and Bolanowski, Marek and Bollerslev, Jens and Brue, Thierry and Carvalho, Davide and Castinetti, Frederic and Ceccato, Filippo and Cristante, Justine and Dadej, Daniela and Detomas, Mario and Deutschbein, Timo and Ferrante, Emanuele and Elenkova, Atanaska and Gil, Joan and Ghigo, Ezio and Gilis-Januszewska, Aleksandra and Giordano, Roberta and Goth, Miklos and Greaud, Cecile and Greenman, Yona and Guelho, Daniela and Ilovayskaya, Irena and Kaniuka-Jakubowska, Sonia and Kastelan, Darko and Kocjan, Tomaz and Komerdus, Irina and Krsek, Michal and Maiter, Dominique and Moros, Olga and Kozamernik, Katarina Mlekus and Papakokkinou, Eleni and Reimond, Giuseppe and Ragnarsson, Oskar and Reincke, Martin and Sigurjonsdottir, Helga and Strasburger, Christian J. and Tabarin, Antoine and Tóth, Miklós and Vila, Greisa and Zilaitiene, Birute and Santos, Alicia and Webb, Susan M. and Valassi, Elena}, doi = {10.1016/j.ando.2026.102490}, journal-iso = {ANN ENDOCRINOL-PARIS}, journal = {ANNALES D ENDOCRINOLOGIE}, volume = {87}, unique-id = {37011974}, issn = {0003-4266}, abstract = {Objective: The aim of the study was to investigate bone comorbidities and their management in patients included in the European Register on Cushing's syndrome (ERCUSYN). Design: A retrospective multicentric cohort study and on-line survey. Methods: We analyzed the prevalence of osteoporosis (OP) and fractures among 1682 patients with Cushing's syndrome (CS), at initial evaluation and during follow-up. All the ERCUSYN partners received a survey addressing bone disease management in CS. Results: Seven hundred and sixty-six patients (45%) had DXA examination at baseline, of whom 157 (21%) presented OP at spine and 103 (13%) at hip. Risk factors for OP were older age (P = 0.038) and lower BMI (P = 0.022). An X-ray was performed in 492 (29%) patients and fracture was detected in 87 (18%). Risk fac tors for fractures at baseline were male sex (P < 0.001), muscle weakness (P = 0.026) and bone mineral density (BMD) at hip indicating OP (P = 0.026). During follow-up, spine BMD deterioration was more common in older patients (P = 0.005) and in those with diabetes mellitus (P = 0.024), while worsening of hip BMD was more frequent in patients with hypopituitarism (P = 0.021), diabetes mellitus (P = 0.034), on levothyroxine substitu tion (P = 0.008) and those less often treated with anti-osteoporotic agents (P = 0.022). The survey evidenced significant heterogeneity in terms of timing of bone evaluation and treatment initiation. Conclusions: A significant number of patients with CS experienced OP and fractures. Clinical factors may help to select patients at the highest risk. There are currently no standards of care for the management of bone complications in CS across Europe.}, keywords = {DIFFERENTIATION; CORTISOL; MASS; fracture risk; Cure; MINERAL DENSITY; GLUCOCORTICOID-INDUCED OSTEOPOROSIS; excess}, year = {2026}, eissn = {2213-3941}, orcid-numbers = {Tóth, Miklós/0000-0002-8701-408X; Tóth, Miklós/0000-0002-8701-408X} } @misc{MTMT:36169319, title = {Kétoldali, malignus reninoma hat évtizedes története}, url = {https://m2.mtmt.hu/api/publication/36169319}, author = {Bényei, Erik and Tőke, Judit and Piros, László and Patonai, Attila and Illés, Anett and Forika, Gertrúd and Nagy, Péter and Kósa, János and Lakatos, Péter and Tóth, Miklós}, unique-id = {36169319}, year = {2025}, orcid-numbers = {Illés, Anett/0000-0001-5351-9015; Lakatos, Péter/0000-0002-7652-3671; Tóth, Miklós/0000-0002-8701-408X} } @misc{MTMT:36169321, title = {Az S-GRAS prognosztikai pontrendszer vizsgálata a mellékvesekéreg karcinómák Semmelweis regiszterének beteganyagán}, url = {https://m2.mtmt.hu/api/publication/36169321}, author = {Bényei, Erik and Huszty, Gergely and Laki, András Miklós and Jakab, Zsuzsanna and Kiss, Gergely and Kovács, Attila Kristóf and Borka, Katalin and Uhlyarik, Andrea and Eitler, Katalin and Igaz, Péter and Tőke, Judit and Tóth, Miklós}, unique-id = {36169321}, year = {2025}, orcid-numbers = {Igaz, Péter/0000-0003-2192-554X; Tóth, Miklós/0000-0002-8701-408X} } @article{MTMT:36169287, title = {A phaeochromocytoma peritonealis implantálódása – phaeochromocytomatosis}, url = {https://m2.mtmt.hu/api/publication/36169287}, author = {Bényei, Erik and Laki, András Miklós and Kiss, Gergely and Varga, Zsolt and Tőke, Judit and Tóth, Miklós}, doi = {10.59063/mba.2025.78.2.9}, journal-iso = {MBA}, journal = {MAGYAR BELORVOSI ARCHIVUM}, volume = {78}, unique-id = {36169287}, issn = {0133-5464}, abstract = {A phaeochromocytomatosis – a phaeochromocytoma peritoneumon való egy-, vagy többgócú implantálódása a tumor sebészeti eltávolítása során kialakuló ritka szövődmény. Esetbemutatásunkban egy sebészeti szempontból irreszekábilis, két ciklus I131-MIBG kezelés mellett progrediáló phaeochromocytomatosisos beteg 14 éves kórtörténetét ismertetjük. A tüneti alfa-, és béta-blokkoló kezelés elégtelensége miatt a beteg szisztémás tirozinkináz-gátló kezelését tervezzük.}, year = {2025}, pages = {118-121}, orcid-numbers = {Varga, Zsolt/0000-0002-1717-9233; Tóth, Miklós/0000-0002-8701-408X} } @article{MTMT:36169316, title = {Bilateral and malignant reninoma - case presentation}, url = {https://m2.mtmt.hu/api/publication/36169316}, author = {Bényei, Erik and Remport, Ádám and Patonai, Attila and Tőke, Judit and Piros, László and Illés, Anett and Forika, Gertrúd and Nagy, Péter and Kósa, János and Lakatos, Péter and Tóth, Miklós}, doi = {10.1530/endoabs.110.EP579}, journal-iso = {ENDOCR ABSTR}, journal = {ENDOCRINE ABSTRACTS}, volume = {110}, unique-id = {36169316}, issn = {1470-3947}, year = {2025}, eissn = {1479-6848}, orcid-numbers = {Illés, Anett/0000-0001-5351-9015; Lakatos, Péter/0000-0002-7652-3671; Tóth, Miklós/0000-0002-8701-408X} } @article{MTMT:36425658, title = {Peritoneal implantation of pheochromocytoma – pheochromocytomatosis: a case report and mini review}, url = {https://m2.mtmt.hu/api/publication/36425658}, author = {Bényei, Erik and Laki, András Miklós and Kiss, Gergely and Varga, Zsolt and Tóth, Miklós and Tőke, Judit}, doi = {10.3389/fendo.2025.1679629}, journal-iso = {FRONT ENDOCRINOL}, journal = {FRONTIERS IN ENDOCRINOLOGY}, volume = {16}, unique-id = {36425658}, issn = {1664-2392}, abstract = {IntroductionPheochromocytomatosis, defined as the implantation of pheochromocytoma cells to the intraoperatively opened surfaces during surgical manipulation, is an infrequent complication of surgical intervention of pheochromocytomas. Only a handful of pheochromocytomatosis cases have been reported since the first case was described in 2001.Case reportIn 2011, a 33-year-old male patient presented with episodic palpitations and hypertensive surges triggered by physical activity. Imaging revealed a left adrenal tumor, which showed intense radiopharmaceutical uptake on 131I-metaiodobenzylguanidine ([131I]MIBG) scintigraphy. Urinary analysis of metanephrines confirmed pheochromocytoma, and laparoscopic left-sided adrenalectomy was performed. Owing to the large tumor size, intraoperative fragmentation was necessary for removal. The patient remained asymptomatic for five years. In 2016, recurrent paroxysmal symptoms prompted imaging, revealing a lesion at the left renal hilum. During the reoperation in 2017, multiple peritoneal tumor deposits were observed and later confirmed histologically. Over the following years, the patient received conservative, symptomatic treatment with tolerable paroxysmal symptoms. In 2023, worsening symptoms led to the decision to commence three cycles of ([131I]MIBG) therapy, followed by alleviation of symptoms, and a decrease in biochemical parameters.DiscussionAn extensive literature search for publications from the past 25 years identified 22 pheochromocytomatosis cases whose details were also summarized and analyzed. This condition appears to have a longer recurrence-free survival compared to patients’ cohorts with metastatic pheochromocytomas. Pheochromocytomatosis is usually characterized by a prolonged asymptomatic postsurgical interval, emphasizing the need for long-term follow-up with close biochemical and radiological surveillance. Treatment strategies parallel those used for advanced/metastatic pheochromocytomas.}, year = {2025}, eissn = {1664-2392}, orcid-numbers = {Varga, Zsolt/0000-0002-1717-9233; Tóth, Miklós/0000-0002-8701-408X} }